TY - JOUR
T1 - Association of Mediterranean Diet With Cognitive Decline Among Diverse Hispanic or Latino Adults From the Hispanic Community Health Study/Study of Latinos
AU - Moustafa, Bayan
AU - Trifan, Gabriela
AU - Isasi, Carmen R.
AU - Lipton, Richard B.
AU - Sotres-Alvarez, Daniela
AU - Cai, Jianwen
AU - Tarraf, Wassim
AU - Stickel, Ariana
AU - Mattei, Josiemer
AU - Talavera, Gregory A.
AU - Daviglus, Martha L.
AU - González, Hector M.
AU - Testai, Fernando D.
N1 - Funding Information:
Administrative, technical, or material support: Isasi, Sotres-Alvarez, Mattei, Talavera. Supervision: Lipton, Sotres-Alvarez, Talavera, Testai. Conflict of Interest Disclosures: Dr Lipton reported receiving personal fees from Abbvie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Avanir, Axsome, Biohaven, BioVision, Boston Scientific, Ctrl M Health, Dr Reddy’s Laboratories (Promius), electroCore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Satsuma, Supernus, Teva Pharmaceuticals, Trigemina, Vector, and Vedanta outside the submitted work; receiving grants from Amgen, Teva Pharmaceuticals, Satsuma, and National Institutes of Health (NIH); being the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York; receiving support from the Migraine Research Foundation and the National Headache Foundation; serving on the editorial board of Neurology, as senior advisor to Headache, and as associate editor to Cephalalgia; being a reviewer for the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke; holding stock options in Biohaven Holdings and CtrlM Health; and receiving royalties from Oxford University Press, Wiley, and Informa. Dr Mattei reported receiving grants from the NIH and Robert Wood Johnson Foundation outside the submitted work. Dr Testai reported receiving private donation from Louis and Christine Friedrich. No other disclosures were reported. Funding/Support: This study was supported by grants R56-AG048642, RF1-AG054548, R21-AG053760, and P30AG062429 from the NIA of the NIH as well as grants HC65233, N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236, and N01-HC65237 from the National Heart, Lung, and Blood Institute of the NIH. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2022 American Institute of Physics Inc.. All rights reserved.
PY - 2022/7/14
Y1 - 2022/7/14
N2 - Importance: The Mediterranean diet may reduce the burden of Alzheimer disease and other associated dementias in Hispanic or Latino people. Objective: To investigate the association of a Mediterranean diet with cognitive performance among community-dwelling Hispanic or Latino adults. Design, Setting, and Participants: This cohort study analyzed data from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA), an HCHS/SOL ancillary study. Cognition tests were administered in the HCHS/SOL from March 2008 to June 2011 (visit 1) and in the SOL-INCA from October 2015 to March 2018 (visit 2). Participants included in the present study had completed a diet assessment at visit 1 and neurocognitive evaluations at visits 1 and 2. Data were analyzed from September 2021 to May 2022. Exposures: Mediterranean diet adherence was ascertained using the Mediterranean diet score (MDS) and was categorized as low (MDS: 0-4 points), moderate (MDS: 5-6 points), or high (MDS: 7-9 points). The mean of two 24-hour dietary recalls was used to calculate the MDS. Main Outcomes and Measures: Cognitive change between visits 1 and 2 was calculated by subtracting the cognitive score at visit 2 from the cognitive score at visit 1 and adjusting by the time elapsed between visits and cognitive score at visit 1. Neurocognitive tests administered were Brief Spanish-English Verbal Learning Test (B-SEVLT) Sum, B-SEVLT Recall, word fluency, and Digit Symbol Substitution Test (DSST). Results of each test were z score-transformed and the means were averaged to create a global cognition score. Complex sample linear regression analysis was used to ascertain the association between MDS and neurocognitive performance at each visit and neurocognitive change. Results: A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. Mediterranean diet adherence weighted frequencies were 35.8% (n = 2112 of 6321) for the low adherence group, 45.4% (n = 2795) for the moderate adherence group, and 18.8% (n = 1414) for the high adherence group. In the fully adjusted model, z score-transformed cognitive scores at visit 1 in the high vs low adherence groups were higher for B-SEVLT Sum (β = 0.11; 95% CI, 0.02-0.20), B-SEVLT Recall (β = 0.16; 95% CI, 0.07-0.25), and global cognition (β = 0.10; 95% CI, 0.04-0.16) tests. In the mean follow-up time of 7 years, cognitive change in the high vs low adherence groups was less pronounced for B-SEVLT Sum (β = 0.12; 95% CI, 0.05-0.20) and B-SEVLT Recall (β = 0.14; 95% CI, 0.05-0.23), but not for word fluency, DSST score, or global cognition score. Conclusions and Relevance: Results of this cohort study suggested that high adherence to a Mediterranean diet was associated with better cognitive performance and decreased 7-year learning and memory decline among middle-aged and older Hispanic or Latino adults. Culturally tailored Mediterranean diet may reduce the risk of cognitive decline and Alzheimer disease in this population.
AB - Importance: The Mediterranean diet may reduce the burden of Alzheimer disease and other associated dementias in Hispanic or Latino people. Objective: To investigate the association of a Mediterranean diet with cognitive performance among community-dwelling Hispanic or Latino adults. Design, Setting, and Participants: This cohort study analyzed data from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA), an HCHS/SOL ancillary study. Cognition tests were administered in the HCHS/SOL from March 2008 to June 2011 (visit 1) and in the SOL-INCA from October 2015 to March 2018 (visit 2). Participants included in the present study had completed a diet assessment at visit 1 and neurocognitive evaluations at visits 1 and 2. Data were analyzed from September 2021 to May 2022. Exposures: Mediterranean diet adherence was ascertained using the Mediterranean diet score (MDS) and was categorized as low (MDS: 0-4 points), moderate (MDS: 5-6 points), or high (MDS: 7-9 points). The mean of two 24-hour dietary recalls was used to calculate the MDS. Main Outcomes and Measures: Cognitive change between visits 1 and 2 was calculated by subtracting the cognitive score at visit 2 from the cognitive score at visit 1 and adjusting by the time elapsed between visits and cognitive score at visit 1. Neurocognitive tests administered were Brief Spanish-English Verbal Learning Test (B-SEVLT) Sum, B-SEVLT Recall, word fluency, and Digit Symbol Substitution Test (DSST). Results of each test were z score-transformed and the means were averaged to create a global cognition score. Complex sample linear regression analysis was used to ascertain the association between MDS and neurocognitive performance at each visit and neurocognitive change. Results: A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. Mediterranean diet adherence weighted frequencies were 35.8% (n = 2112 of 6321) for the low adherence group, 45.4% (n = 2795) for the moderate adherence group, and 18.8% (n = 1414) for the high adherence group. In the fully adjusted model, z score-transformed cognitive scores at visit 1 in the high vs low adherence groups were higher for B-SEVLT Sum (β = 0.11; 95% CI, 0.02-0.20), B-SEVLT Recall (β = 0.16; 95% CI, 0.07-0.25), and global cognition (β = 0.10; 95% CI, 0.04-0.16) tests. In the mean follow-up time of 7 years, cognitive change in the high vs low adherence groups was less pronounced for B-SEVLT Sum (β = 0.12; 95% CI, 0.05-0.20) and B-SEVLT Recall (β = 0.14; 95% CI, 0.05-0.23), but not for word fluency, DSST score, or global cognition score. Conclusions and Relevance: Results of this cohort study suggested that high adherence to a Mediterranean diet was associated with better cognitive performance and decreased 7-year learning and memory decline among middle-aged and older Hispanic or Latino adults. Culturally tailored Mediterranean diet may reduce the risk of cognitive decline and Alzheimer disease in this population.
UR - http://www.scopus.com/inward/record.url?scp=85134427855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134427855&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2022.21982
DO - 10.1001/jamanetworkopen.2022.21982
M3 - Article
C2 - 35834250
AN - SCOPUS:85134427855
SN - 2574-3805
VL - 5
SP - E2221982
JO - JAMA network open
JF - JAMA network open
IS - 7
ER -